Reviving the FDA: NEJM perspective

October 6, 2010

In a Perspective piece published online today in the New England Journal of Medicine, Georgetown University School of Medicine family medicine physician Susan Okie gives a comprehensive overview of change, and planned change, within the Food and Drug Administration (FDA). The review comes as the FDA's commissioner, Margaret Hamburg, completes her first year as the agency's leader.

Okie writes that the FDA's priorities over the past year have included "finding ways to make the FDA more nimble and proactive, restoring its and refocusing staff on its public health mission, persuading Congress to boost funding for its expanding portfolio of responsibilities, [and] sharpening its ability to deal with new science and globalization…"

To that end, Hamburg reportedly has spent hundreds of hours meeting with interest groups and meeting with key members of Congress to build alliances.

As Okie outlines, Hamburg and the deputy commissioner, Joshua Sharfstein, have already undertaken several changes at the agency. The two leaders have met with FDA employees to understand hurdles they encounter because of legal and regulatory requirements. Such discussions have prompted new measures to accelerate responses to urgent health threats. In nonemergency situations, changes that have been described as "nuanced" actions often achieve desired results, Sharfstein says.

Hamburg, Sharfstein and internal task forces have been "reexamining the processes for making decisions" about the safety and effectiveness of drugs and medical devices. Okie says the agency is awaiting reports next year by Institute of Medicine panels that are likely to recommend reforms. The leadership anticipates decisions that could lead to lasting changes at the agency.

Finally, Hamburg's longer-term priorities include regulatory science and globalization. The Commissioner tells Okie that in addition to advocating for increased funding, the agency hopes to collaborate with scientists in academia and industry, as well as other federal health agencies, on research and training in areas such as biomarker, bioimaging, clinical-trial analytics and pharmacoepidemiology.

As for , Okie reports that the agency is introducing a risk-based strategy for targeting priority inspections in order to "grapple with the expanding task of ensuring the safety of products… made overseas."

Hamburg says despite the criticism of her agency and the growing pains within "...overseas, the FDA is still considered the gold standard for a regulatory agency," while here at home she says, "I have encountered a sense of real eagerness... to support the FDA in its mission."

Related Stories

Recommended for you

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Justsayin
not rated yet Oct 16, 2010
"boost funding" appears multiple times in this article but when you give more money to an incompetent and corrupt agency you get more incompetence and corruption. The FDA stifles new cancer drug development, delay approvals driving up the costs to astronomical levels and with all of these delays what is the real cost in lives. The story of 19 year old Abigail Burroughs says it all here...http://www.abigai...tory.php
Justsayin
not rated yet Oct 16, 2010
this is the link I meant to post http://www.lef.or...s_01.htm

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.